What is the preferred adjuvant therapy for high-risk non-clear cell RCC?  

Unfortunately, non-clear cell RCC (nccRCC) has not been included in past or current adjuvant trials. Sunitinib, which has limited effect in the adjuvant setting, would be expected to have even less in nccRCC given relative activity in the metastatic setting. A similar scenario exists for IO adjuvant...